It’s critical that we all work together to reach the World Health Organization’s goal of #HepatitisC elimination by 2030. Ahead of #WorldHepatitisDay, we’re emphasizing our focus on #HCV elimination and advancing progress in the global community. Hear more below. [Video description: An interview with Dimitri Semizarov, global medical affairs therapeutic area lead at AbbVie. On-screen text reads, “Together, global leaders can help eliminate hepatitis C by 2030. Join us in helping move the world closer to eliminating Hepatitis C.”]
About us
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.
- Website
-
http://www.abbvie.com
External link for AbbVie
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- North Chicago, Illinois
- Type
- Public Company
- Specialties
- Biopharmaceutical, Biotechnology, Innovation, Research and Development, Manufacturing, Biotherapeutics, Oncology, Immunology, Virology, Neuroscience, Womens Health, Aesthetics, and Eye Care
Locations
Employees at AbbVie
Updates
-
Through our sponsored #research conducted by the PD Avengers, we gained a deeper understanding of how #ParkinsonsDisease (PD) can disrupt the lives of not only the people living with it, but also their care partners. Read more about our commitment to the PD community and advancing research: https://bit.ly/4cOQXLy [Video description: On-screen text states "44% of Parkinson’s disease patients reported that their nighttime symptoms affect their care partners emotionally, and 36% reported that their symptoms disrupt their care partner's sleep and physical well-being.” Followed by a quote from a person living with PD: “Parkinson’s doesn’t take a break. It impacts us 24/7.” On-screen text: “We are proud to sponsor the PD Avengers SLEEP survey.”]
-
Shaping the course of patient access through external partnerships is part of the essential work of our #MarketAcccess teams. Globally, they work to unlock the potential of our #portfolio and help get #treatments to patients sooner. Explore our #career opportunities: https://bit.ly/3yeearn
-
-
At the XXIII International Congress of the Brazilian Society of Ophthalmology in June, we introduced our medical education program “Advancing Ophthalmology,” designed to support local #EyeCare professionals in raising the standard of care in their clinics. Explore our research interests and areas of focus in this field: https://bit.ly/3Sh2UBp
-
-
Thank you, Disability:IN and the American Association of People with Disabilities, for honoring us with a top score on the Disability Equality Index and recognition as a Best Place to Work for Disability Inclusion. Learn more: https://bit.ly/3zM2Web #BelongAtAbbVie #BestPlaceToWork24 #AreYouIN
-
-
Meet the experts leading one of the largest #data initiatives in the biopharma industry. See how this platform enables #ArtificialIntelligence tools to transform the future of medicine: https://bit.ly/3Y6b1oj #DataScience #AIAppreciationDay [Video description: Four AbbVie employees discuss the importance of data and meaning of data convergence].
-
Join us in congratulating our team of #scientists who received the American Chemical Society's 2024 #HeroesOfChemistry Award for their discovery and development of a medicine for #autoimmune diseases. This award is the highest honor for industrial chemical scientists.
-
-
Seramount has named us to their list of 100 Best Companies. This honor reflects our inclusive work environment that supports families, working parents and caregivers. Learn more: https://bit.ly/3W7KBzD #BelongAtAbbVie #Seramount100Best
-
-
Sometimes, breaking through scientific barriers requires inventing something new. With over 600 novel instruments under their belt, that’s just what our SPaRCS team has done. Hear two scientists on the team, Andrew Radosevich and David A. Chang-Yen, share how SPaRCS is developing technologies that enable life-changing therapies. This is how we’re building the lab of the future: https://bit.ly/4cyMNaz [Video description: AbbVie scientists Andrew Radosevich and David Chang-Yen share an overview of the SPaRCS team. On-screen text reads, “People. Passion. Possibilities.”]
-
In June, we partnered with the International Agency for the Prevention of Blindness (IAPB) to lead a session on diabetic eye conditions at 2030 IN SIGHT LIVE in Mexico City. The session brought together global experts for a critical conversation on the importance of a multisectoral approach to improve care for people living with diabetic retinopathy and diabetic macular edema. Explore our research areas and efforts in #EyeCare: https://bit.ly/4fcBI0L #2030InSight
-
Affiliated pages
Similar pages
Browse jobs
Stock
ABBV
NYSE
20 minutes delay
$172.32
1.18 (0.69%)
- Open
- 173.67
- Low
- 171.22
- High
- 173.845
Data from Refinitiv
See more info on